Home › Employers › DesigneRx Pharmaceuticals, Inc.
DesigneRx Pharmaceuticals, Inc.: H-1B salaries and sponsorship
DesigneRx Pharmaceuticals, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $130,000.
Does DesigneRx Pharmaceuticals, Inc. sponsor H-1B visas?
DesigneRx Pharmaceuticals, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 12, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Quality Control Manager | 3 | $130,000 |
| Director-MSAT | 1 | $180,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 4 | $130,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Director-MSAT | $180,000 Level IV | Vacaville, CA | Jun 12, 2024 | Jun 21, 2024 | Certified |
| Quality Control Manager | $130,000 Level III | Vacaville, CA | Jun 8, 2024 | Jun 17, 2024 | Certified |
| Quality Control Manager | $130,000 Level III | Vacaville, CA | Jun 7, 2024 | Jun 17, 2024 | Withdrawn |
| Quality Control Manager | $130,000 Level III | Vacaville, CA | May 31, 2024 | Jun 17, 2024 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).